US Oncology Reports Fourth Quarter and Fiscal Year 20...(ical oncology services $529.4 $...)

oncology

services $529.4 $524.5 0.9 $514.1 3.0 $2,088.2 $2,080.4 0.4

Cancer

center

services 87.1 81.8 6.5 89.1 (2.2) 349.9 323.9 8.0

Pharmaceu-

tical

services 599.7 520.0 15.3 568.2 5.5 2,282.8 1,995.7 14.4

Research

and

other 12.3 12.5 (1.6) 11.9 3.4 51.2 53.2 (3.8)

Elimina-

tions(1) (456.9) (417.2) (9.5) (439.5) (4.0) (1,771.3) (1,641.8) 7.9

Total $771.6 $721.6 6.9 $743.8 3.7 $3,000.8 $2,811.4 6.7

Operating

income

(loss)

Medical

oncology

services $19.3 $25.2 (23.4) $15.6 23.7 $79.7 $124.5 (36.0)

Cancer

center

services 20.1 19.2 4.7 22.9 (12.2) 87.7 77.5 13.2

Pharmaceu-

tical

services 28.1 20.2 39.1 21.6 30.1 90.9 79.8 13.9

Research

and other (0.3) 0.4 nm(4) (0.8) (62.5) (0.8) - nm(4)

Corporate

costs (2) (32.9) (27.9) (17.9) (32.0) (2.8) (128.8) (117.2) (9.9)

Impairment

and rest-

ructuring

charges(3) (6.8) - nm(4) (1.0) nm(4) (15.1) - nm(4)

Total $27.5 $37.1 (25.9) $26.3 4.6 $113.6 $164.6 (31.0)

EBITDA

Medical

oncology

services $19.3 $25.2 (23.4) $15.6 23.7 $79.7 $124.4 (35.9)

Cancer

center

services 29.9 28.9 3.5 32.9 (9.1) 126.8 116.0 9.3

Pharmaceu-

tical

services 29.4 21.5 36.7 22.9 28.4 96.1 83.7 14.8

Research

and other (0.2) 0.6 nm(4) (0.7) (71.4) (0.3) 0.9 nm(4)

Corporate

costs(2) (20.3) (16.7) (21.6) (20.2) (0.5) (83.6) (75.0)(11.5)

Loss on

debt

extin-

guishment

(3) -
'/>"/>